Trials / Completed
CompletedNCT00036556
Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer
A Phase III, Randomized Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 941 (actual)
- Sponsor
- Abbott · Industry
- Sex
- Male
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
This study is being done to evaluate the safety and efficacy of atrasentan in men with non-metastatic hormone-refractory prostate cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atrasentan |
Timeline
- Start date
- 2001-06-01
- First posted
- 2002-05-13
- Last updated
- 2007-08-15
Locations
234 sites across 17 countries: United States, Australia, Austria, Belgium, Canada, France, Germany, Greece, Ireland, Italy, Netherlands, New Zealand, Poland, South Africa, Spain, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT00036556. Inclusion in this directory is not an endorsement.